Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Weekly News Recap #Phispers


1. (2s)-2-((2-((4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)propanamide
2. Gdc-0077
1. Gdc-0077
2. 2060571-02-8
3. Rg6114
4. Gdc0077
5. Ro7113755
6. Inavolisib [usan]
7. L4c1uy2nyh
8. (2s)-2-[[2-[(4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide
9. (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide
10. Rg-6114
11. Ro-7113755
12. N~2~-{(4s,11ap)-2-[(4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl}-l-alaninamide
13. Propanamide, 2-((2-((4s)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)-, (2s)-
14. Mfcd31382124
15. Sgeunorsozvtol-cabztgnlsa-n
16. X3n
17. Inavolisib [inn]
18. Unii-l4c1uy2nyh
19. Inavolisib [who-dd]
20. Gtpl9636
21. Chembl4650215
22. Schembl18360780
23. Bdbm295665
24. Amy16810
25. Ex-a2685
26. Nsc800729
27. S8668
28. Us10112932, Compound 101
29. Who 11204
30. Akos040741785
31. At36699
32. Cs-6459
33. Db15275
34. Gdc-0077; Rg6114
35. Nsc-800729
36. Ac-31594
37. Ms-26989
38. Hy-101562
39. A903455
40. Gdc-0077;rg6114;ro-7113755
41. (2s)-2-((2-((4s)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)propanamide
42. (2s)-2-({4-[(4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-9-oxa-3,6-diazatricyclo[8.4.0.0,tetradeca-1(14),2,4,10,12-pentaen-12-yl}amino)propanamide
43. (s)-2-((2-((s)-4-(difluoromethyl)- 2-oxooxazolidin-3-yl)-5,6- Dihydrobenzo[f]imidazo[1,2- D][1,4]oxazepin-9- Yl)amino)propanamide
44. (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)propanamide (gdc-0077)
| Molecular Weight | 407.4 g/mol |
|---|---|
| Molecular Formula | C18H19F2N5O4 |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 112 |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 641 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Phosphoinositide-3 Kinase Inhibitors
Agents that inhibit PHOSPHOINOSITIDE-3 KINASE activity. (See all compounds classified as Phosphoinositide-3 Kinase Inhibitors.)
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Inavolisib is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of breast neoplasms.
Lead Product(s): Inavolisib,Ribociclib,Fulvestrant
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Inavolisib,Ribociclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Inavolisib is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of breast neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 12, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Inavolisib is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of breast neoplasms.
Lead Product(s): Inavolisib,Fulvestrant
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 27, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Inavolisib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Inavolisib is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of breast neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Itovebi (Inavolisib) is a Small Molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of Colorectal Neoplasms.
Lead Product(s): Inavolisib,Bevacizumab,Fluorouracil,Calcium Folinate,Oxaliplatin,Irinotecan Hydrochloride
Therapeutic Area: Oncology Brand Name: Itovebi
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 07, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Inavolisib, Bevacizumab, Fluorouracil, Calcium Folinate, Oxaliplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Itovebi (Inavolisib) is a Small Molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Itovebi
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 07, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Inavolisib is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Prostatic Neoplasms.
Lead Product(s): Inavolisib,Enzalutamide,FoundationOne® CDx (F1CDx) Assay
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Inavolisib,Enzalutamide,FoundationOne® CDx (F1CDx) Assay
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Inavolisib is a small molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 17, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Inavolisib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Liver Failure.
Lead Product(s): Inavolisib,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 27, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Inavolisib,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Inavolisib PK in Moderate or Severe Hepatic Impairment
Details : Inavolisib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Liver Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 27, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Itovebi (inavolisib) is a kinase inhibitor indicated with palbociclib for treating endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer.
Lead Product(s): Inavolisib,Palbociclib
Therapeutic Area: Oncology Brand Name: Itovebi
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 23, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Inavolisib,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EC Approves Roche’s Itovebi For ER+, HER2- Breast Cancer With PIK3CA Mutation
Details : Itovebi (inavolisib) is a kinase inhibitor indicated with palbociclib for treating endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer.
Product Name : Itovebi
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 23, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Inavolisib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Inavolisib,Ribociclib,Letrozole
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 08, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Inavolisib,Ribociclib,Letrozole
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Inavolisib Treatments in Early-Stage PIK3CA-Mutated Breast Cancer
Details : Inavolisib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 08, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
GDC-0077 (inavolisib) is a PI3K alpha Inhibitor in combination with palbociclib and fulvestran, which is currently being evaluated for the treatment of HR+/HER2-breast Cancer.
Lead Product(s): Inavolisib,Fulvestrant,Palbociclib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 27, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Inavolisib,Fulvestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Genentech’s Itovebi Extends Survival in HR-Positive Breast Cancer
Details : GDC-0077 (inavolisib) is a PI3K alpha Inhibitor in combination with palbociclib and fulvestran, which is currently being evaluated for the treatment of HR+/HER2-breast Cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 27, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Inavolisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Inavolisib,Palbociclib,Letrozole
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Inavolisib,Palbociclib,Letrozole
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Inavolisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 24, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
FoundationOne®Liquid CDx to be used as a companion diagnostic for Itovebi (inavolisib) for adults with endocrine-resistant, PIK3CA-mutated HR+/HER2-breast Cancer.
Lead Product(s): Inavolisib,Fulvestrant,Palbociclib
Therapeutic Area: Oncology Brand Name: Itovebi
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 11, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Inavolisib,Fulvestrant,Palbociclib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves FoundationOne®Liquid CDx As Diagnostic For Itovebi™ in Breast Cancer
Details : FoundationOne®Liquid CDx to be used as a companion diagnostic for Itovebi (inavolisib) for adults with endocrine-resistant, PIK3CA-mutated HR+/HER2-breast Cancer.
Product Name : Itovebi
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 11, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Patents & EXCLUSIVITIES
ABOUT THIS PAGE
99
PharmaCompass offers a list of Inavolisib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Inavolisib manufacturer or Inavolisib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Inavolisib manufacturer or Inavolisib supplier.
PharmaCompass also assists you with knowing the Inavolisib API Price utilized in the formulation of products. Inavolisib API Price is not always fixed or binding as the Inavolisib Price is obtained through a variety of data sources. The Inavolisib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A GDC0077 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of GDC0077, including repackagers and relabelers. The FDA regulates GDC0077 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. GDC0077 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A GDC0077 supplier is an individual or a company that provides GDC0077 active pharmaceutical ingredient (API) or GDC0077 finished formulations upon request. The GDC0077 suppliers may include GDC0077 API manufacturers, exporters, distributors and traders.
GDC0077 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of GDC0077 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right GDC0077 GMP manufacturer or GDC0077 GMP API supplier for your needs.
A GDC0077 CoA (Certificate of Analysis) is a formal document that attests to GDC0077's compliance with GDC0077 specifications and serves as a tool for batch-level quality control.
GDC0077 CoA mostly includes findings from lab analyses of a specific batch. For each GDC0077 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
GDC0077 may be tested according to a variety of international standards, such as European Pharmacopoeia (GDC0077 EP), GDC0077 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (GDC0077 USP).